<SEC-DOCUMENT>0001193125-13-369153.txt : 20130917
<SEC-HEADER>0001193125-13-369153.hdr.sgml : 20130917
<ACCEPTANCE-DATETIME>20130917160354
ACCESSION NUMBER:		0001193125-13-369153
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130912
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130917
DATE AS OF CHANGE:		20130917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		131101338

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d598583d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(D) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): September&nbsp;12, 2013 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>000-30171</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>68-0359556</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>501 Canal Blvd</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Richmond, California 94804</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) 970-6000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01- Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2013, Sangamo BioSciences, Inc. issued a press release announcing the presentation of clinical data from its program to
develop a ZFP Therapeutic (SB-728-T) for the treatment of HIV/AIDS at the 53<SUP STYLE="font-size:85%; vertical-align:top">rd </SUP>Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference to this Item&nbsp;8.01. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and
Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">Exhibit<BR>No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Issued on September 12, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE: September&nbsp;17, 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SANGAMO BIOSCIENCES, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">/s/ EDWARD O. LANPHIER II</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Edward O. Lanphier II</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President, Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d598583dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 99.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g598583001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Sangamo BioSciences, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Point Richmond Tech Center</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">501 Canal
Boulevard</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Richmond, CA 94804</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">510-970-6000 <FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT> 510-236-8951(Fax)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES ANNOUNCES PRESENTATION OF CLINICAL DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEMONSTRATING FUNCTIONAL CONTROL OF VIREMIA IN HIV-INFECTED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBJECTS TREATED WITH SB-728-T </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Sustained Reduction of Viral Load at or Below Limit of Detection during Treatment </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Interruption of Antiretroviral Therapy </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Additional Presentation Demonstrates Notable Depletion of HIV Reservoir </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Richmond, California, September&nbsp;12, 2013 &#150; </B>Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data from its
ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of Sangamo&#146;s novel ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, SB-728-T, for the treatment of HIV/AIDS. The data demonstrate
functional control of the virus at or below the limit of detection in CCR5 delta-32 heterozygote HIV-infected subjects treated with SB-728-T. The abstract was selected as a &#147;late-breaker&#148; presentation at the 53<SUP
STYLE="font-size:85%; vertical-align:top">rd </SUP>Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). On Wednesday, September&nbsp;11, data were also presented demonstrating depletion of the HIV viral reservoir in SB-728-T
treated subjects in cohorts 1-3 of the SB-728-902 study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from the late-breaking presentation demonstrate that viral load (VL) became undetectable
during a treatment interruption (TI) from antiretroviral therapy (ART) in three of seven evaluable CCR5 delta-32 heterozygote HIV-infected subjects, including two of six subjects that had completed TI in the ongoing SB-728-902 Cohort 5 study and an
additional subject from an earlier Phase 1 clinical trial of SB-728-T. In one SB-728-902 Cohort 5 subject, VL has remained undetectable (at or below the limits of quantification (LOQ) of the current ultra-sensitive assays for HIV) for seven weeks
(to last measurement taken) and the TI is ongoing. Reduction in VL from peak during TI showed a statistically significant correlation (p=0.015) with estimated numbers of engrafted ZFN modified cells (SB-728-T) in which both copies of the CCR5 gene
had been disrupted (biallelic modification), in line with previously presented data from this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The data presented today demonstrate that a
single infusion of SB-728-T can lead to profound suppression of viral load in the blood and sustained functional control of the virus,&#148; stated Dale Ando, M.D., Sangamo&#146;s vice president of therapeutic development and chief medical officer.
&#147;This is the first evidence that sustained functional control of HIV in the absence of ART is possible. The fact that three of the seven evaluable CCR5 delta-32 subjects achieved undetectable levels is a major step toward immunological
functional control of HIV. We look forward to following these Cohort 5 subjects and presenting a complete data set from this study by the end of the year.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a presentation on September 11, 2013 entitled &#147;<I>Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on
Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T)</I>,&#148; data were presented that demonstrated that treatment of HIV infected subjects with SB-728-T leads to a long term increase in CD4 counts. The effect on
total CD4 counts in </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SB-728-T-treated subjects was significantly greater than those observed in previously published T-cell infusion studies without CCR5 modification and correlated with increased CD4 central memory
and increased CCR5-disrupted central memory cells. In addition, a median 0.6 log reduction decrease in the size of the HIV reservoir at twelve months was observed, as demonstrated by measurement of HIV total DNA in peripheral blood mononuclear cells
(PBMCs). The decrease in reservoir showed a statistically significant correlation with the improvement in CD4 count. Finally, data were presented describing possible predictors of robust CD4 T-cell reconstitution and immunological response post
SB-728-T infusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These data are extremely important and suggest that an immunological approach to control of HIV infection is obtainable,&#148;
commented Rafick-Pierre S&eacute;kaly, Ph.D., Co-Director&nbsp;&amp; Chief Scientific Officer of the Vaccine&nbsp;&amp; Gene Therapy Institute of Florida (VGTI Florida), and a collaborator on the study. &#147;SB-728-T treatment results in an
unprecedented and durable increase in CD4+ cells primarily due to the expansion of central memory cells - CD4+ T-cell types that are vital for the successful reconstitution of the immune system in HIV-infected individuals. This enables functional
control of virus and effects on the latent reservoir of HIV-infected cells that cannot be cleared by ART.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Central and transitional memory T-cells
remember previously encountered foreign invaders, such as viruses or bacteria. These cells can survive in the body for the individual&#146;s lifetime and reactivate when they re-encounter the same antigen. On reactivation they produce a faster and
stronger immune response than the previous encounter. SB-728-T seems to both expand the total memory pool and, by CCR5 modification, protect a proportion of that pool from HIV entry, suggesting that SB-728-T treatment has the potential to durably
reconstitute and protect an effective immune system in HIV-infected individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are amassing a body of data suggesting that SB-728-T treatment
can potentially enable attacks on HIV infection from several angles,&#148; said Geoff Nichol, M.B., Ch.B<I>., </I>Sangamo&#146;s executive vice president of research and development. &#147;Our aim is to provide a protected reservoir of immune memory
cells to replenish the cells killed by HIV and to generate an effective immune response against the virus and opportunistic infections. Some HIV-infected individuals, so-called &#145;elite controllers,&#146; can accomplish this without drug
intervention. These individuals typically have low CCR5 expression and good anti-viral CD8 responses, a characteristic shared by those SB-728-T treated subjects in which we have to date seen the greatest effects on the virus. We have demonstrated
that SB-728-T treatment results in a durable increase in total CD4 T-cells and, in these presentations, an effect on controlling the acute rebound in viral load off ART, and a longer term effect on the viral reservoir, a source of HIV which is not
addressed by current anti-retroviral therapies. The data will be used to optimize the development of this therapy as a functional cure for HIV.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Nichol added, &#147;In addition to our SB-728-902 Cohort 5 study, we have a second ongoing trial (SB-1101) designed to maximize the engraftment of
SB-728-T in subjects who are not CCR5 delta-32 heterozygotes and who represent the vast majority of HIV-infected individuals. Maximizing circulating SB-728-T is important, as viral control appears related to the extent of engraftment. This trial is
evaluating escalating doses of a preconditioning drug, cyclophosphamide (Cytoxan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), which is used to transiently reduce the numbers of T-cells in the body. The cells rapidly repopulate once
the drug is discontinued, an effect that can enhance engraftment of concurrently administered exogenous T-cells such as SB-728-T. We intend to present data from all dose-escalation cohorts in these studies before the end of 2013.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SB-728-T </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo&#146;s drug, SB-728-T, is
generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient&#146;s own T-cells. ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach
is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to
the most common strain of HIV. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Clinical Trial Design </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SB-728-902 Cohorts 1-3 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study is an open-label
Phase 1 clinical trial to evaluate the safety and tolerability of single infusions of an escalating dose of an autologous (a patient&#146;s own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial
enrolled nine HIV-infected subjects (three cohorts of three subjects each) who have sub-optimal T-cell levels and no detectable viral load on long-term ART. Subjects remained on their existing antiviral therapy while receiving treatment with
SB-728-T. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SB-728-902 Cohort 5 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to 20
HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART are being enrolled and will receive a single intravenous infusion of SB-728-T (5 to 30 billion modified
cells). Two months after SB-728-T treatment, subjects undergo a 16 week TI during which time their ART is discontinued. ART will be reinstituted in subjects whose CD4 T-cell counts drop to &lt;350 cells/ mm<SUP
STYLE="font-size:85%; vertical-align:top">3</SUP> and/or whose HIV-RNA increases to &gt;100,000 /mL for three consecutive weekly measurements. At the end of the TI, subjects with a sustained detectable HIV viral load are reinstituted on ART.
Subjects with an undetectable viral load can remain off ART until HIV RNA levels are detectable or their CD4 T-cell count drops below 350 cell/mm<SUP STYLE="font-size:85%; vertical-align:top">3 </SUP>for three consecutive weekly measurements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of ten subjects have been treated in this cohort. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of
the six evaluable subjects, we observed two subjects in which their VL became undetectable during TI from ART: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In one subject, VL suppression at, or below, the limit of quantification (LOQ) of virus was sustained from week 11 &#150; 19 of TI and the TI is ongoing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the second subject there was a transient suppression of VL at or below LOQ. The subject remains off ART. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
third subject completed the TI with 1-log decrease in VL from peak. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In three subjects, there was no reduction in VL during the TI, one completed the TI
and in two the TI was terminated early due to their viral loads exceeding the upper limit allowed in the protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A seventh subject has not completed TI
and is still being evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The non-employee authors of these abstracts have no financial relationship with Sangamo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sangamo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences, Inc. is focused on
research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of HIV/AIDS. Sangamo&#146;s other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and
beta-thalassemia, and a program in Huntington&#146;s disease. Sangamo&#146;s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic
collaboration with Shire AG to develop therapeutics for hemophilia, Huntington&#146;s disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including
Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company&#146;s website at www.sangamo.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Sangamo
BioSciences, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release may contain forward-looking statements based on Sangamo&#146;s current expectations. These forward-looking
statements include, without limitation, references relating to research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo&#146;s ZFP technology platform for the treatment of HIV/AIDS, including a potential functional
cure for HIV/AIDS, the ability of a ZFP Therapeutic to control HIV infection, projected timing of release of SB-728-T clinical data, the expansion of clinical studies for HIV-infected individuals and the initiation of additional preclinical studies
of ZFN-gene modification. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical
trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo&#146;s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of
these and other risks, please see Sangamo&#146;s public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no
obligation to update the forward-looking information contained in this press release. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Sangamo BioSciences, Inc. </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elizabeth Wolffe, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">510-970-6000, x271 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ewolffe@sangamo.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g598583001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g598583001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`8`"F`P$1``(1`0,1`?_$`'@```(#`0$``P$`````
M``````D*``@+!P8!!`4#`0$`````````````````````$```!@(!`P,#`P,#
M`P0#```!`@,$!08'"`D`$0HA$A,Q%!5!(A91,B-A0A=2)"5Q@9$9<E,8$0$`
M````````````````````_]H`#`,!``(1`Q$`/P!_#H)T$Z"=!.@Y?EW-V&L`
M4]WD'.>5L=8=HS$3%=6W)ERK])KR:I4CK?;EE;$_CVBKHR29C%2(8RA@#T*/
M0!P?>2!Q:2V9Z7KW@[)63-K<P9`M,53ZM4=:\/W"\EDYF5=D:D%M89IM5:N\
MC8],3N';IN]60;,T5%SF^,@CT%5N:3R0G7$OGYGK<STMM>5K/-X^KV0ZUDFT
M9';T#&\_%3;B18N4H!*/J5LEYL\%*1:S1Y[CLS)."?VB0R9SAX7A7YW-WN5[
M+V3;#:M:]<<!Z7:^5>0G\[9>=VN^/;!$R#Z#FI&JU^MS$M)1M:.[1+$JR,PX
M=,@;,8AJH<YTU5FQ5`!GRL^77LG><I63%G&7)1.&L*563?0S?/$Q4(.V90RN
MNS<D1&P5^(NL7+UNBTUR=`PLD%(YQ*N43%666;B<6J8<#U+\Q3D2PO5[56=C
MZAC/;9RXK,FA0;E/1K/%EPKEQ%JY"%D+2KCV(8URYU1)\HF9VQ)'1T@JF003
M?I]_0&B^(_D:V_S?P-[`;QVQ]&9PVDQB\W&NT`C=DEV=<L3^C'D\D0%6590"
MT:Y:U>%8R?XY@R;*H&2:-DFY%"`4#``'\/>;IL-&23-//NDF&[G"?(!7SG$M
M_N>.9DB(AZJ((6UODN/<+`/^T3(E'Z=P^O0,5\>?D[\>7(%D_'F`8F*S1A3/
MN394T!4J#?Z0:PPD[.E:KO"L(N]4!S8XM%)1LU4."\HA%)%`O[Q+T!<:5R#Z
M-9%RY<,!TS;3`$YFRA6:5IMKQ4EDZKM+W%VF"D%HF9@BUJ1D&<G(2$9)MU$%
MB-4UOC53,4?4H@`7#^GH/03H)T$Z"=!.@G03H)T`Z]_N5;1[C1IO\FVHS+$U
MZQOV2CNIXBK!26O,5X$@E(0M=HL>N#U!BHH;VC)2)V$2D8.RCH@]@$$J;SY5
MG(3O?N+@77+C^Q]4M::9D_-^/<?0(6&#@<KY6N3:QW"(C#K6Z2GX]S4*O$&8
MJ**NVL6R,NV0!3_R*@![N@*/YJL/C57C\UOL%@C!<90CMIV<'CB53<KHJ1T'
M.8VNDAD)NJU*?[=TRD0K<4)O>43IK(I"0P`)@,%5?"<U=Q4[Q]MIN1*P;&7S
M'&Y$B-?Z?,OVJ+AS2:8G48:[VD]?54(8[%Y=7]@:(/%2""@MXPB8"!%%2G"W
MGF?:_4^Z\>V%]B%HYJ3(6#MB(.IQ<V"*8/3T7+=:L3:S0)U^P*G:KV.JPKLI
M1$0(=L;L`>\W<!8IK.=$?#FCY_'J@0-^Y`<NNXF_6!B7XY!W"Y!R%9J_)1RC
MDO906LGA7"Q(I0HC[02?+=@[G-W"UWAHZ(X(L&O&>MV\A8[J%\RQ(9H=84Q[
M,6V!C;"?']2IU0JEFGG-63E4'2$1,6R9N94W;I(A7(MHY),IRIG5*<!L^9?K
M5AS#.Z6MV4\74BM46=SQA6QNLF,ZK%LH1C8K)0+:C%QUOD(V.20:#.R,+.I,
MW#D"`=RG'I"<3'*)A`[''^W2T`\3&\91MG_;2UYU@V-RT@UD"_"FI-["O[)4
M\2M"D.("=.78S<`)0_WBO_0>@1TRIJS4<(\.>L>Q=IJ+%?,>ZVW.5I''UP<)
M*_DJ[K[K73@H<I`L#"L4B:5ZRM?'#MWW(/R)0;(2B'8W<'Z?$NTUP!BOC%Q;
MM57Z-7GVP&QL]E&1O649",8OK:Q@ZADNV8Z@*)7YE9-5]!U5G&54KI=HW.D5
MT_=K*K>__$"8)5[^:ZQ.UOD;9XUEQ03^.,<U;_-\<+/8("D/!R%@M,,RR?:F
MG;_&1Q'2YI>4./H0JA#?0.@>^YK\D9]XD.'>H6+0_,5FITOK;D/"E+3M.5?Q
M6;+A:,8RTO)5=:MSDQDB-G0DW2LW,QIS+BD51-BS%NB*2?8`!?W1;S-\]JSM
M7QSN5J=&YK7EWR$4E>-8R/J[DEXLNL0B1D\2RZDY`6V4.F)A%)A(PP','8B8
M=^P!H"XVO47E''=$R7!1EEAX7(-/K=UB8BY5^1JENBXVT0[.:91]HJ\NDA*5
MVP,VSTJ;QDX(59LN4R9P`Q1Z#VG03H)T$Z#E.9\ZX7USHDCD_/>5<?X;QY$F
M*F_N62;7"T^O(KJ%.9%H61FWC-!P^<`F;XT$A.LIV'VE'H%U>??D2WIH&AE#
MS]Q(-Z_E+!-\B[7/YGW*P]*UG)[K$M#BB1[*-<4^):K2:;1"6=.WPR5D!L\+
M7@C3)J%:K'!=(,US7;"VR')UN=C7"T=:[/DW.^Q=_:0\E?\`(,W.6V2;(*`K
M(6B]7&<D7#^8=0M.K;-U)/#"<YP:M3%3`3>PH@4KB-Q=7]2?(ZP'@BY/S6&/
MPMN3ES!;.;DF)(U69L$-'9+QI1YY6-!5P1@YD+.9@Z(B"A_A4.4`,/M[]`R#
MYP#U^G@/06-(90(UUE[-3UV4._QF?L*;2T&!CC_;\A&\DY]OZ]C&[?KT'+_"
M*V)APBMWM39!T@A.C)8]V%J30R@%<2,8=HYQU?EDR"/<Y(E=O70'M]/N_P!?
MT`L?E[H'6X<[,H7M[6NQ>"UU._?O[#/K$U#V]@'U^1R7Z_IT`0]@(W_G;PN-
M:[-"I&=+Z_9+K\C.)H`)S,PK>QV4,3N55BD[@4I&.0&ZQA'Z%/W'H+]>$]E=
ME/Z1;888^8II?&FR\9>U$/>'O)"95QQ`Q4:H"??W`0\IC%^'?Z=^@%YYLSIQ
M([J:5UQ$/<9/6F;=-R";L07$YEB>8=O[?V^X8@@"/<?3MZ>GJ!VO(VHCG#'C
MG$Q-2R'9US'D1IECB11;A[`"J52?HL*U35%("E$JDQ&,?D$?0PCZ_7H%T>37
M$#3)?B_<,^P=#;$>0V`K/;L?W/[0I1_$J90E[M$V.2>`F`_$F.1\<-VYS&[=
MUGZ??U.'0&1\,C>"&R-JAE[1&POD4;WKG<Y#*E"9J*>U67Q%E22*O.`T3,81
M5&I9*%T=V8``"$G6H?41'H%7YJ_RVBODJ63)>8EEF"6,>3RRVJ[R3[WE$N/+
M[E^0?NK#[ENQA9N,<7(KY(_J`H'*8O<!#N#I?F%V"1CN(!-G%D5<Q]LVDPI$
M2[EL(J-THA*'O]F;.%U$_<3[9:7@692F$?:*AR>O<0Z!6'P[6^.77+3(DND3
M$R-H0UARP]Q2YDVZ#A>(N3:<H?Y.0A!7`PMYH:(I+I`JF'RE:*+@`@4QN@O#
MY;.>M^]6>1K`61<4;&YVQ'B*R8$@WV(28SR1;Z56V-YIULG4,E(+QM?DV$7*
M6`#2<.Y=G=)KF59O&R1^Z1"E`/.<6OF!9OQC,US$W)?#CF[&"ZK:,+L12X5C
M%9BIB)S(H$DKE58=NRKV2X=HF`F7.T0CYDI/<IW?J^U(P:'&'LQXLV!QG3LR
M84OE:R;B[($,WGZ?=ZE(I2<'.1;D!`%4%T^QT'+=4ID7#98J;EJX3.BLFFJ0
MY`#I70#9Y1^4#7SBIUND\\9M=GF[%+*.H##V(89\V;7#+=X(V!9.%B/G*J$9
M`Q1%".)B643.A&M!`?:JX5;-EPRN-_\`8SE*Y89^P;H9TQ7GJT8-@?R"M+_A
M6+<CGUJPQ4B&.)HZK23>)=UAJFW01_\`(S#MRJ_>JD$[IP(%(0@,^^%QLDC?
MJ)NWQ^9$7_DE/-%1&:ZA4IA0KV*-6K@DKC'-$21BX$Y?Q<F=Q7S+(%#XC'<K
M&$ON5,(A3#QB<5T3"/D"[2X9EDB!*8?H^W&-\8?D.QW2<K1LP5BJ.%&YC_N_
M(FH;"1`PA^X4#*_H(]!4?R$,=VWCPY\YK8ZH-'#)M<+]AG=G&[I)([9%Y+HR
MT8[M[<CCL"2JRF3:/+"N`"(_&Y*)@_?Z@S-Y8V/X[;WAUP+N/BP5)JJXWR%B
M7.+5Z@D"YSXCSY3C5E&1.9'W@F0LW;*^940_:4ON$1[%Z!"#C`WXO?&INIA[
M;"DMEYEE3I5:%R134ER-R7[%-F*2-O=1,HKW03>.XL?N8]50!(VE6K5<0$$N
MPAHZ^1)<L>[L^/;E38?`%D:7[&DPCK_G.HV",'W%=UE+*]2C)<'K8/<M'RD"
MVFG2,@T5`J[%VV516*4Z1P`!)>.@5EO=P)<E_'4\51?6ZL*Y33IT<8Q#+M$L
MRXW)9<8OB)*_M]C/,-%D'`"'H4X!W$!$.@&AX>FTIL&<F-RUQLCT(R"VNQ)/
M5-LQ=F%#OE3$JKF^U,BA3B4"N`K*%E:E*(>XRSDA0]1Z`I7FDZC95L`ZB[O4
M"J3-BIF,8:UX>RK,P\>XDDZ,J]L<9;L9S,XDW26%C!RTF\EF@NU0!N1Y]NB<
MP'<)%.#"_)'C6=WDX%LU1TA6G32]Y%T:J.<F=6<-5&\G&W^G4BKYP90'VBR9
M5VTBG/5W[(R8E!0#&,3MW].@7>\=&K0')EP/[[\9%S=-E)6G6ZTM**L[,0W\
M7-E:%;9&Q+8"%.!A31@<WTN2?']H?N*!BB/8_;H%9>'G:ZW<8_*W@R]W7[NH
MQE<RP^U]V+@Y$PMBQ]%M\Y_Q[D9M.(F.F4QZ-)^R7`AA[%>PZ8_[>@/[YG^C
M+.B9XP)O_28TI(//D$IAW+CEDD`M`R3CN,2?4&P.W"2?QG>7#'9U61>YA[IU
MHHAZF'H"*:_YH'G)\87/^$I)8EEVFU9Q2TJ%A8*G.YGYFZ:[(1N1L.VY`H$%
MRN^RI1:D6,47$!^YEOR!`[@`]`D-Q);1N=,^233S807QXZ#I^:ZK#WI4%!2(
M;&]\<&H.12+>H%,4E-LKU0H&[@"A"F[=P#H-%_RT]2VVQ/%+9LMQ,8B^NVH]
M_JV9(A\D4#O@HLXY2H.1XY!0H&'\>:,L326<E#]H_AB&'^P.@6$X7^&35?EX
MXG-FF4*B&/=^<+Y[GOX#EX9F5/&O8::QW49>@4>^US[I>*4Q]89:.EVIG:#4
MDBP=`=TFHL1,[58.#\(_*_G;A&W0M6GNW#2RU_6R>R@ZQ[L+C2S"Y4>8$R,U
M>A`FR_5&O=8B*,>JFE^<2:@9":A`*X2^59!H80U5/Y'7OX]_+OSL1_$_PO\`
M)/Y-^19_@/X[]C^4_/?E_F^P_#_C/^X^Y^3X?A_?[O;Z]!F09JSS4.7+RC<8
M8NV7?%G=6<?;-RNNV/<<S+M0M4=U;#1;,9G77+(RQ4%2YLRQ6/=)@'^5XC*$
M:>X4TD0*&G$P@(**@VM7BX2(C:RQC$X1E7&$:R9P+.&1;`S2B&L.W13CV\8D
MT#XBMR)@D5/]H%[>G0)!ZZZ@PO&?Y:<10,/5PM/P'N=KQEW(-)KD8@+6`@(Z
M>J$Y<;?4H9NEV;-XJ"RQB595FT(!4V,>[;)$`"$+T`K=\9"<X;_*3A=F7A5H
M+$>4LR53/CF1;D,@TE<,;%(.J7GD.PE%%52$GWMH[)^O91HBH(![B]`:3S,]
M.T\M::8*W7J+-.0F-:KX:FW*08!\P.<19N&,:Q\LNX1]Y'#.#R%#Q*3<>_M*
M$VL<!["/0=-\=C(],Y2>"7)VAN87P2LABF#R'J?:ONP*X?L<=7B'?6'#%K:D
M,/<BE3;RQV48;ZI+5HI@]2AV!+/C]XW$-C]P=L.+;+18^A;0)5#+D'@6V29E
M&K."V<UOFG<P>GS*QB_*:@Y+ID38&3M4I%#)#]F]335,W(0P7DX?MSK[KNMN
M+P6[P(2],Q-M95\RX#@8*_"=L?73;6>@92J0`*E<G,2.J][MB;5JZ^$3-R3!
M6#],Q$E':R@=/\.S/,IA[E(OFOLPHLQC]A\%WBLN8E<XI>V_8B?M[[#'71$P
M%,Z85Z.L*!?J8HN#`'U'H!7;0+S/%SSGY6L=124C?_Y>WM=Y+J[%O[D@6H)L
M@M\APD+[2_N%E,8\G$FAR^OO07$![]^@V.X:7KE_J<-8(P[&P5.Y0,5/Q:JJ
M2+R/EX*=8-Y2-<BBJ"J#AN[9.4U"]P,40$!Z#]61C6,Q'/X>3:I/(R48NHR0
M9+%`R#I@^;J-'354@A[3(K-U3$,'T$H]N@SN?%O/+Z=<V7(-H=,*+-F"U7S%
M3468J#\3NRZXYG:,ZR[]A@#Y14IL[+JIF[=_C4_UZ`/7E#ZOM=9^8+/CR#BP
MBJEL/$4_8^NI(HE1;G?7Y@M&W]9+XRE3$[O*%:FG)^WJ`N`[_7H&X-X$1Y*?
M$WJF9YK_`,]?Z/K#B3.8RO<57`9`USD&U3RI+&-V$1<O(."LB:OIZ_<&^GIV
M!6+Q5-VW>JG*/2,43LI]OBG<J&<X&MS!TL0L86[*@O.8AFU$5C%24D`M[881
M(1[B"$^N'8>_0"&Y+L',]9^0G<W!<.5-"%QGLEEF!K2;</C3;5@+C)R%612`
M.WL^WK[QL7T[>I?H'TZ#7?U^<0O(OQ&8K1M0$?,-M]%("N6PSL".1+,9%PZG
M7+(LI[^Y#.6%@=+G`1]2JI@/U#H$GO#-R;/XHY!-P]5;`JJU+=<(/9J0BS'4
M!-.\8&R5'0`]D3]B@HG&7^4*8>P'[$*`^@=!W7S0./R$@)C!7([CZOIL'5UD
M4\`;!N&#<J:$G/L(AU-8@N,C\?\`?*.H")E(9TX.'<Z$?')]_P!OJ'EL$<FN
M1<R^)#O#1D[J_9YMT[9X@U=DIHKDAIF1U^S)G#$M%JY55`.*Y&SK%UKG:B!Q
M`#_;Q?N]WN'OT`F_(@X\,X<:?)1<-DL?M;/`X7SWEE]L)K]F*N%=M4:?DN0G
M`O%EHYYQIW)`W6C74ZSR.3,<JKB*,V<)"8Q5RI`P%QH^8_BNP5ZFXJY+*!.T
M:]-$V,&\V5Q9$A/T*Q_&1HT3L60,<L_99*A(K#[U7RL(25:**>XZ31HGV2*#
M;$+B/4';;*&KW(;27M8RS:\4T3(T=KWF>BVX\K5W%,S-%,X:WD]L.]/"SXBU
M8G12!T0R\8X4<D`$U3JEZ!1/S><+Q#K%VBVQ"#5).>A+YE#"TJ]*F`+O8BT5
M^)O$`U65#L)DHMY49(Z91[@`O#B';N/<#PZC57_[0O'LQ!CC(J@R,KL-HB3%
M,G*N^RZ_\[J5;?4&$MRAEOE]\@RNU/;2A3F$3_.F!N_N]>@3H\/K8*QX#Y/\
MJ:FVH'44SV&Q3<JU(U]VL=N9CEC`SM[<8T5VQ_VB]CZRVL[4Q?0W=7]>W;H.
MY\]4"'&/Y$^IF_U19_BZGEN6P]G2UBW^9LT>S-.L1,4YRB2G3[%`T]CYFU<N
M_:(B=67.8P?O]0M%YAO&I"FKV.>5G"$45A/L96J8RV/=5U,4B2L;($!'#V8'
M#AJ8H)2$4_11KKIWZG73=110$/@$3`K9P29/F*7S,Z#W5>3<'D[+LC"5.8D%
MUC"N_#+:$O09@[I3N`JG?DMRGO[_`-QC=!=SRUJ!'TKF;RS,,$BH_P#)N'\&
MW]Z0@%*4T@%,)1G*O[?43+_P@IS"/J)C#^G;H'<=!^7C2#7?B[XTWVY&T>.\
M.WF]ZC8Y3B(FV*S3B<L$=C=J?%CZ?)'0<3+O",E)>H+)"NJ4A%%TU`*(B4W8
M".ZP\JW'?N?D)7$^KNU^,LQY(0KLA;#TVM*SK>=_CL2LS;R<LFTFX6*^9LP6
M?H@K[!$R?R%$0[#T"%!-ML&Z!>6MLCL#G&Y+8_PC!YCSK'7^S,H&>LYF9[_A
M"10134A*O'RTV\*[OLFV(I\+=04C&^0P`4IA`*_^4AR&:0<C>=]6,I:;Y1=Y
M//1L37;'^2'KJAWBD?C"IW%K8J<@F%V@(!>3!S^;E3"*!#E1]H>\0$X!T#3/
M"Y#'OOBQS-4L!`58R^MV_%<0*N(JIEC7%AS<BU/[1^A$55A.!?T$.@S$\27^
M8Q1E;&64J\Z.QGL;9!IE^A'I!,!VDO3['&V&.<E$@@8#(/(XA@[>OIT%B>1'
M82*VPWIVRV0@`.6NYESQD6\5L#E4(?\`C4M87@UWW$6*55,1A4T/VF`#%^@^
MH=!J>>,C?W&0.%'3)=TK\SFI,,J4`Q_7N#>I9DOL=')"(B(_X(KX"?T[%]/3
MH%*N"8Z-<\I;9N!AB?;Q+C)O(A7BMT@]B:<9'WBX2#5O[0-V!)%:&1`H>O\`
M:'0-J>37CF'R)PI[D&E$$U7-#C\7Y&@EC@'O9S%;RY2$_G1-V'VJ*Q4BZ0'^
MJ:Q@_7H,R73?+LG6M*.73#(+*C`Y5U>UPM;EJ43_`!#8,6<A&IJ4,\4``$G=
M")OLFD'?L(_-]?3L(;..:<&X?V/QM9,/9XQK3\MXPMS4&EBI%Y@V<]!2!"")
MD''VKQ,XM)%DKV4;.T#).6JP`HDH0Y0,`(H\L/A\M8F$M><>+>?EWZ\6U?SD
MIJ3D*7&2?OV[=(7*S/#&1I)4CEU(`4A@;PL^<ZBX^B<E[_C0,`J?&?Y3\I<?
MF\U>TVS-+6",UOV.R&EB>Y4"W%>L38;SS)R1*U4[HSB94$5ZO(+6DB4%8VQB
MH`HV<`LX(99@B``?KS;[`U:Z;Z9U0ZI0>S6S-FL#='T]RC2LXMFXUXH'Z^U)
M:UH`/_YAT`Y>+'@)WGW(X_->]C\8\M^<-;*CD6,N#FJX3A1R\I6:5%061+96
M?9$JUO-U6BR(S+J%4D!*WC6Y"G="`^XWN.(#,T)P=:^/_P`F/`FN\YD97*%H
MQ9N&EB^?R4+%Y$KWA7(=8D827G'3!_*S;U%>6;W505@6=N%#*"8QCF$>@/[Y
MP5.C'&']`;^**03,1DK.--(X]O\`F/&6&L4*;.B)_P#]:3JL%-V_J?H&B%L*
M5O>KB5K6$KXV+(1&R6BF/XATJZ*"JS.=MV&H"4K]A2^3Z2E>M!VLBW./J1RV
M(;ZAT&29Q6P,VRY6M`JZDF<DY%[QZ[1ZZ:7N$4G,3F:KDD.P]@'V(E:J"(]O
M[0'H#">82Z1<<P3M),WN.QUAPBU<!_T+'=W=Z4H_^J#P@_\`OT!!=\=1<=VO
MQ(=!,^VJ$8H9AUQAZ)9*%;1023FSTO/&99R'GJ4H]^,%EX"696V.E`0$1*5S
M%I')V[G]P7'\)#%%`0UOW*SB$%%+91E<XUG%2UE59HJS3"AUZA0ML:PK)^<@
MN&<;*3]I76<I)F*1PHU1,H!A13]H!XTMUWP3RI^3KMK7L[4QOD_`S_,&YF09
M^J.I.:C&,_"TN4G:;2U59*O247+(-6TV^C'2?Q.">_XBE'N41*(?=\KKCVT8
MX^K=I95=.\*1.&Y/(]:S7/Y%:Q5FN=@_-L(*5QU'5%PY);K%/F:"V</I0I#(
M"D"@"8#`;VE[`TSJ(R3T^\5B/F9P@QSJ-XW\VY/5!<@(JC+9JK%_OD`B8A_;
M[G*KF^-$4R_50WM`/4>@RF35*S$J:5Z-!R1:<O87%20LIFJ@0ZUF:1K68=0:
M3T0^)22;1;U%PHD`B8B2I##V`Q>X>^:8+R2\P-.;*D@Q3Q#`Y8K>$G-E64$A
M761[/4K+>&<#'I>P0<J,JU5UG#LWN+\`+MP[#\H=@U2?$]3.QX3\#N7@BBW4
MR3L,^(HJ/8A6B>6K.F=4/0/:D!VYQ_7U[CT"M'C)/CYG\A#8#+Y0,=)U4]P\
MJF5#]Y0->,D13!(3G]0_R%N9NP_KVZ!M[R@,GQ6-.%7;-O(."HO<EKXGQ?`(
MB(`=]*S^5JC*N6R7<0$QT:_`/G!@#N/L0-^G?H,VK2C"TC8>//F8SXHT5&"Q
M?KOJ?CA-Z*:@(EL>6N0+6:::(D6[?$8Y87%SX3D[^X`.4?IT#+_ER\G&YV(=
MPL8:?8-S-DS`F)ZYA.J9:FG6*K7.T"P9'N%TLEK8%=35HK;J,G'=?J[&K)(-
M&)')6H.U'"JI%#_%\0,;^-=GS>/87C9@[1O;&9!5O5=R79ZEB_(.4XF1A[[E
M3#S&&K,C7K9.A+M6<I8/LYR4D8QO,K$$\FW8D.=190IUU03E\DO"U+;>01CN
MK:_Q;>-R1FE/5J>NT;7$"(*'SE=+FK7V<H#=J``C.ST&QA'SDP%`Z[A<7!_<
MHL8Y@MAYM&<R6'8_2O69@^,]<XSP]=LKSS-$?>(2F6[6PJL*51$@=RO!8XJ6
M4`.P]R.2]OKT#P_&7KV?57CYTWU\<MQ;2V,]?,;1-G0$OM$MTD*^TGKP8P!Z
M`96W2STX_P"H]!G4:ISQ-L?+>3NT`55]#N.0+.5PCG*'9P4]9PJRR"^BY#WD
M[A]HM&T-`X&^@$.`]`7SS?;D@>B<>.+&RI3RLY><]7,S,#%^048F'QE7&*OM
M_O`BCBQ+%[]NPB'0.<8TBFFO^IN/X-8"MF&$M=*K%*@N/8K=GC?&;!HH"QO0
M`*DC##[A]/IT&41XY^,W&Q'.'JE(.43JLZO?\C9\FCB7W?;_`,#IUNN,4LJ8
M?0ONM@1Z?<?]QP#ZB'0>W\G6V/<V<Y6QM4JZ*DO(U_\`X)PU!,&H"JJZG&V+
MZ052-0`O?WKJV2P+)^T/4%#"7Z@/0'Z\I2^QFE_$CQT<8=>?-4Y^4B<:-+6T
M:&!3YJ/K!C>%KKI=8>X&*G8,DV!BZ2.(?Y3QZOT[#T%D?%402U/X0=K]N+:7
M[&'?Y,V"S6U<.BF20<U#"&(ZY#"X2.<0*LF:QU*60[E^JB8E^H=`+/PN<;S&
M1=[-SMEYQ-=\K3\#H59Y*J%$2'M><,G1MF64%0Q1]SE=GC-\(]A[@4_K]>@K
MGY..09?>OG2Q[J%0')7RN.&.`]3X#[0IUTQR%E:PM;5/N!*7W>Y:/DLG-6+C
ML'8AHX0'^T>@:+\H3(L-J3P;RN"*:HA&,\CSV`]6ZFS*)454JE5/M[:_0;(I
M^T/B+5<5&:G`/VE(OV_IT"E6_P#I]$:P^-WQ4V!S&)M\A;`;,WK86SN_MP3=
MN6N8\72BU31.8P?.=-/&M+K8`4?V@H!A``$P]PLUS"Z?1O'QX['%_KS*Q:47
MEK*.Q9]B<PD,0J3]?(=QPU;9.:92)0*0RCFDP-CA:\)A[]BQI?\`JZ!F/C#G
MV^E?C"47++]V2+=4[2K/^>&[M0`3[S%U<Y+R!42E[B'R+/'$\P12#ZG,<H!]
M0Z!?WPC\.O9G8[=K81TT7.QI6&Z)B=G(JD,**DMDZZKVZ03(L8.QG2#+&"0G
M`![@1<._]P=!Z#S/>0"O76^8(X[\=V1.3'$KMQG#8!M&O`69Q]ZL$-^'Q74)
M($3"4LW`U"2DY1RB?O\`&C-LS>ANX`%IL3<-V7<1^*CM-B&$IKM?:_:VKT+;
MJ\4Y5FY"RH0V-\EXLR[5\7HQX)_?'L\?B/&ZHIQPD^4M@E%V_;W#T!9_(EX5
M$.537Z)R#AMO'1NY6OT7++XK</'"$='Y4ISM0)&>P[89)?VH,UWCI,7E?>+F
M*@RE#'24,DW>N%DP$#P"^0>IB%2*XO.5:5F,19+Q')I8IQ!F;*R3Z$4CPA%B
MPC'"F=G<P5->KS=:,D1I#SKT2,UF92-GJB*B*3AT%,^.BG?_`&0>6+LIGBSO
MVEOI6N.6L\9BBWK-VVF81Y"X0EV.",$DC9%JJX8N&D7(O8.1;+(F,DL+#WE'
M]_<0JQR%Q[C?#RO&6'K,49"IH[?ZYX06C%2BJBCCW%4;11N[$$C]BB@]"*F7
M)R@``)G)A^HB(AI?[(9%'#^O&>\LD.5,V+L+Y1R$D81`I2GI=(G+"EZ_0``T
M<'09L7ASXD=Y6Y3\F9QG5%GRN%==LAVH9%QW656N>4+)7J.DLLN?N/W#R#FI
MHXB(^XW8W^O06@\HV>5S[SE\>VKS4#O&,%5=>*NNQ[BHD$]FW8*8"5+\/<0`
MZ]?:1?O'M^XH%#].@=5Y;\K)81XP]]LDBY!BM!ZKYCC8I<#?$8DY:Z=)4VNI
MHG`0]BZTY/MTTA#Z*&#H$>O">P8%DV_VTV+?L2GC\08$@<=1D@L7LFTG\O7-
M"65.BJ8/C*JG`8P=D4]0,!%_Z"/<*C\96-R\I/DRVK+D@U";QU7]H\W[?6%1
MPG]PV+2L77:0DL6MW!3E%(6SJVK5EF*8A[?B4,`>@=P#GOE9Y]F]A^9#)&-8
MITYFHG7NE8LP+4(IK[E2_FWL&VOUG0:(%$0/(.+ED%=J?M^XPMB%'^WH&S>4
M&EL^+/Q=I'6B(428V5/!F(-=I-1(2HFE;]F.UPS_`#8Y2+V*949892RN!+Z&
M!$P_]/;H.,>'5C>!PIQ?[*;064`8(Y$SK<966E%2`GVQ_@G'T.F@L"IO0[9E
M,2\Z/<1[`?WA^G0+C<`\1+<B?D.1^R.0$U90["^;`[HV9-P)E@;2A7$LM242
MF5[B1*!O5XAA;E[A["-"@'H7MT!E_-OR`^D8OCIU_BUC&6L]LS;D!XR]YO8N
M^8H8UI576.0/03$-99(A1'U[''M^O0&(Y1..%YL=7.#G52&KSZ2Q5A/:?%B&
M4V[>/%Q%1.),)Z^6&9EQGE!2.W8,9EG0"P:9E!`JCN523`#&.7H`5>;QD\\E
M>./O`,:4ZKJ/KN:,GNF"'[E%36J8HM+K12MR?N$YU*M($3[!ZB(@'0$K\AN[
M,M$O'@Q3JI`N&\/,Y"K>L&J$?'$'VNSPE&JT7<;PLB0.PBBHQQH9JY/]/^_`
M!_OZ!9_BPYV<.<27%EF?%.$*78KYO[G3,ULLS:1L,$V:XEQC!$J-9J=*M4U*
MJO5'=T<0:;!V]:0J#8J2SU<Q72R2(?Y@N+X[?"5EO?//27*KR&L;%8<2FO#O
M*F.XG)2*KJP;3Y9<2ZLP.1;$UDB`HYQ-7YL!<@=1,&\^^(F@B4[%%P"@:1'<
M>_?OZ]!\=`!WF`X!-3>5^'<7E\4F"]L(F&&/K&P=1AF[I2P(LT#%BJ]EZL)K
M1Z%_K[8P%31<BLA,,$@`C=U\`"W.`#/'PXW]SN'KE@RICW;#$4DGB_-&MN0Z
M;0]E*.@_M."9F5IUGIN34!>WENQ20I"DC5:E)G^SL*<2[!9`I`3-[B&.`FL1
MYGQ9:O+FB,LTJZ5J\XTN?(/98ZJ7:N2S28J]A5N,3-4B$?04TR54CY6/<V25
M23;.$%%$5_VF3,<IBB(:`O,_<'%#XG>0VQM5OMW*6IV8HA!7O[>RUGJCZKID
M`P"`@94\P!0_U'H%)?!VK\>>?Y%;49(II5O#:W5]!<>WN2CWC[,4BZ2*']P%
M<.6*(F_0?C#^G05ZY+5W-B\PG7J-G2`+&*V+T$CXLI_4HQ[:"QE-("`*`)``
M99VL/H'83=Q^H]`SCY4M^6H_"GLVS;*F27R!:\'4$HE.)?>C(9@J,Z_2-V$!
M,52.KJP"'Z]`%7@J?,^/SQK=^]\%%2,+GE)?-\Y3I%3V-5#/ZI76F"L0,"+B
M`'5*3+4@^.0/7L+HWM^H]!]GPDM:#,J/NCN+-1RAG-HLU)UZI$LX2*)A95ED
MID/)";=<Y15.D_?6.N@H(#[14:=A[B7T!>386!5REY.]OJMD(4Z5DY<X"MO4
M'9!425AV^QL+$MVJJ:ON][=6':$3[#Z"0>WTZ!N'S2I*<:\9^#6#`RH0TIN1
M3"SX$$03,1GB;,#F,!4`]!`'H=R]_P!0Z#UG&/&?\6>)99IZM")926TQWKNZ
MJJ8"4_Y::F,XI'4`Q``_R(MT$P`WU#V!V^@=`O9X6+B*3Y*,^H.Q2"3<Z<6_
M\0!^WRB*.6\0'?\`P]Q`?1N(>[MW].@N7Y<ZJ!^3GBO;60Y4:82LPBKY9P(@
MT30<;!19+*<XG+\0`G%-VXJ#W$?;V[AV[=PT'![]Q_U'_P"?Z=!E8>2CMO2<
MG\\L>:?<+3F*=/G.OV(K*C&>UZ=RSJ%A1REE=BS0]WQJ23.8NTC&*)]P[N&7
ML-V$!``/AY'FB^\',Y'Z#96XY(JI;'ZG_P#'MKL\9)P62:946Z=KR/(0:C:Z
M2:5[GJRB\A%ZI"-6R)D05=QSE)XBX22,H4#!^=Q/>(5C+"<O6,Y<D]CKN<\@
M1*Z$O":WTQ5=UA2#D$3IK-#Y(L#UHRD\H.&BA`,:-0190HG`2+_D4!$H@[%'
MQ\?$1[")B6#*+BHMDUCHR,CFJ#&.C8YB@1LR8,&38B39FR9MDBII))E*1,A0
M*4```#H/N=!.@G0?R<((.VZ[1TBDY:N456[ELX3(LW<(+$,FL@NBH4R:R*R9
MA*8I@$IBB("';H%H=UO&#TQSKEVI[.ZBS;K0_9.DW^M9+C9?&-:9S6')BUU>
MP,[+'RLAB3\C`-:Y+%E&*:@+P+V,;B;W'6:KG-[N@\=Y/"W*I>]4IK772[5E
M#,NN>6*9'CL;DN@KN+7FJ'4K]I2L*]-K.*&CMO,)UF4;0+-5U)LF\VX6167;
M"FT`OS+`OEX:>P+/!V]6S>H.26DI3[AL#B^(D*O!V&.=Q,F6_8&?V*:E*J]C
M9!-L]CY56EVR6>BFJF4P%C#E$`'L`A6KGOV,@L1>2ZGG&&=I')KGDG2^PV55
M'VG(5]CNMXTM\XU/\8]S*)QB@)*`/[@,`E'Z=`VOY8;%E;.$W+=BC7J3N/BL
MH:[6V/=-CE4;R#*3R'#PK99%0.X*(+-K*"I#!]0`!Z`'^2U`GO":Q@3&JII!
MI7K7")Y+2C!%16.%KNK9%YY*5(B)C)%1FY"/6.!^P?"HF<?VB'0'[\5N!ID)
MPI:SN:BNR</;%:LX3]X5:&(9<+H?+ELB7*$D!1]Q7K2`B8]$H&[&^W(D(?M$
M!$$5>:VX1^J/D89]S#42?<ABS:3`N?3M&RA0,M/MJOB;*MB9>\@_M4>3JKDI
MP^H"H(#T#<'ET7^B9*X7L/Y#J\JRF:_DK9'`-UQW+(*IG)+P5FQADZPL))B8
MON!1%U7WH*?M'^TX#T'[/`?*,=F?&@NN%DWZ#N2@<;[LX`E$"G`QXI_8D[W:
M(5!P43=R#^&R(R<!W[`)5`[>G0)X>,)L]2-7N7S!4ID>Q,:G3<RUJ^8`?V"5
M<I,XME-9#C&[BBH2+M=1-!JWE\@U^*8@JH8$TSN2F,(%`1`&"/-[A*DJSXZ)
MM@_:_P#+))G/\*SA&+DA[&\J+I/%#QM()QZ!AD`:L[(V!)NJ!?:9=P<I!$P"
M``PKQ!;R;F;M:"NIC*VIN2==MDL=8CB:K3+[GB&D:UB;8:_HTV3CZ[DB";.V
MC:]LJ\_GXAJ[GTQBU&Z`/NS%R[#N5,!Y:->*-KICO)LEL[R,Y*=[T[&6ZUS&
M1K36WL>XK^!"WNS2;N=G).9A'2RMFRHX-,O5%0/*JL8MQ[O\L4(=@`&P(2$A
M:U$1E>KD/%U^`A6+:,AH.#CVD3#Q$:S2*@TCXR,8(MV3!BU1(!$TDB$3(4``
M``.@_4Z"=!.@G03H)T$Z"=!PJTZP:Y7;+M$S_:\'8MG,YXR=NGM!S`\I4%_R
M75UGL0_@7:<9=DF:5B(S<0\HX;G;F<&;F35,`D]>@5[Y$?$4UWW!R[E;8G#^
MTV8,.9>RY;K#D"VL,D,6F;*)(6NS2CF5DS,5',A5+Q!QAEW(D11/)R*;1$A$
MD4RI$*0H>_Y7>+/E1V:XF=-N/C#&0\&Y+LN*HNK1FS]JF[/-4!?*[?#4(QA\
M.MJLI-P<F@LBZ.B60F?OG#,YY5@U4(<4Q4#H*[\!/$CR)ZZ8EW9T(Y)\-UYM
MH?LECJ2591;7+=`N4A'9.F18U*P&IS6GS\^_@@LE0]CX[U5)$&DE!L5DNRQE
M/<%+:1I=Y#7`+E#(&,^.NGL]Y--LG6UW8*C$OJVVNL9'2CI-%BSE[?0F5JJ-
MQQG?TXM!NWE'L8Z-79,C9-1103$(DW#GL;XJO(GODQV:W2WWSA2\3;@9L"U9
M*H>'(E"+LJ#W)$H09&)A<J66`>.ZOCZI`FFE%-&,(>:5C6GQ'44#[<S94.V;
M)\'_`#4[&<1?'9HE8F>(7]RURR]FN9N<=/9CATT:ICG[2+B-?F$C8&;62861
M2LQ4_9FI4XXSLS&,,P1`#&*<$P*+P-<(^[W&5BC;O&6>=C\2/*ALW1$&%<I.
M*$+7<B8TR>,)-UM3)1Y2UP=):.'9(.521<,6R1DY`&;83KI_`4!#D>OOAD<=
M6.E&,CGC,>P^Q$HU,@JYC6TO`X?I;U1(Q#*)GC*JPE;F@W6$!#_'8"*%`?0X
M#Z]`TNEKC@4MEQU=WF(<?SE\Q'3&F/<:9"M-9B[9D*ETYD5N"4)!7NRMY6V,
CT%3M2*+J`[^9PJ`J*G.<QC"':Q$1^O0?'03H)T$Z"=!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
